_{^{For Healthcare Professionals Outside the US}}
_{^{Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.}}

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

bban

For first-line targeted therapy in
patients with BRAF V600 positive
metastatic melanoma

5-YEAR OVERALL
SURVIVAL

More than half of patients with
low tumor burden were
alive at 5 years⁶

SEE THE 5-YEAR DATA

bban

REDUCE
THE RISK
OF RELAPSE

12 months of therapy kept
over 50% of adjuvant patients
with melanoma relapse-free at 5 years⁷

FIND OUT MORE

slider2

IDENTIFY THE TARGET.
TAKE ACTION.

Find out more

Efficacy Safety

Nearly 1 in 5 patients with metastatic melanoma achieved a complete response with TAFINLAR + MEKINIST in the Phase III COMBI-v clinical trial⁴

See rates of disease control

Choose TAFINLAR + MEKINIST to reduce your adjuvant patients’ risk of relapse and protect their QOL^1,3,5

Learn more

TAFINLAR + MEKINIST is an approved targeted therapy for treatment of adult patients with BRAF V600+ NSCLC^1,2

Find out more

OS, overall survival; QOL, quality of life.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 3. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823. 4. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. 5. Data on file. Novartis Pharmaceuticals Corp; 2018. 6. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(1):626-636. 7. Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139-1148.

COVID-19 Update

Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20 G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo⁴

ELIGIBILITY REQUIREMENTS

Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
ECOG performance status ≤1
No prior systemic anticancer treatment or radiotherapy for melanoma

TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)

imgh22

Placebo (n=432)

STUDY ENDPOINTS

Primary endpoint was RFS
Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety

COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy